Hypoestrogenism and estrogen replacement therapy in women suffering from schizophrenia

Estrogen Effects in Psychiatric Disorders

Volumn , Issue , 2005, Pages 123-144

  Bergemann, Niels ^a   Mundt, Christoph ^a   Parzer, Peter ^a   Runnebaum, Benno ^a   Resch, Franz ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 11844275445     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-211-27063-9_6     Document Type: Chapter

References (102)

1. Albus M, Maier W (1995) Lack of gender differences in age at onset in familial schizophrenia. Schizophr Res 18: 51-57.
2. Angermeyer MC, Kühn L (1988) Gender differences in age at onset of schizophrenia. An overview. Eur Arch Psychiatry Neurol Sci 237: 351-364.
3. Battey R (1876) Extirpation of the functionally active ovaries for the remedy of otherwise incurable diseases. Trans Am Gynecol Soc 1: 101-120.
4. Beck AT, Steer RA (1987) Beck depression inventory - Manual. San Antonio, The Psychological Corporation.
5. Behl C (2001) Estrogens - mystery drug for the brain. The neuroprotective activities of the female sex hormone. Springer, Wien New York.
6. Bergemann N, Jaggy S, Maier S, Kaiser D, Auler B, Parzer P, Resch F, Mundt Ch (2001) Estrogens effects on neuropsychological performance in schizophrenic women. Arch Women Ment Health 3 (Suppl 2): 20-21.
7. Bergemann N, Mundt Ch, Resch F, Parzer P, Runnebaum B (1996) The hypoestrogenism hypothesis in female schizophrenia: preliminary hormone screening results. Eur Psychiatry 11 (Suppl 4): 403.
8. Bergemann N, Mundt Ch, Parzer P, Jannakos I, Nagl I, Salbach B, Klinga K, Runnebaum B, Resch F (2004a) Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res (in press).
9. Bergemann N, Mundt Ch, Parzer P, Pakrasi M, Eckstein-Mannsperger U, Haisch S, Salbach B, Klinga K, Runnebaum B, Resch F (2004b) No additional effect of estrogen as an adjuvant therapy to antipsychotics for relapse prevention on the psychopathology and the course of illness in women with schizophrenia: results of a placebo-controlled double-blind study (submitted).
10. Bergemann N, Parzer P, Nagl I, Salbach B, Runnebaum B, Mundt Ch, Resch F (2002) Acute psychiatric admission and menstrual cycle phase in women with schizophrenia. Arch Women Ment Health 5: 119-126.
11. Bleuler E (1943) Die spätschizophrenen Krankheitsbilder. Neurologie 15: 259-290.
12. Brockington IF, Kelly A, Hall P, Deakin W (1988) Premenstrual relapse of puerperal psychosis. J Affect Disord 14: 287-292.
13. Burger G (1984) Nerven- und Geisteskrankheiten als Indikationen für eine bilaterale Oophorektomie im späten 19. Jahrhundert. Dissertation, Med. Fakultät, Erlangen- Nürnberg.
14. Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A, Schildkraut JJ, Green AI (2002) Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 111: 11-20.
15. Choi SH, Kang SB, Joe SH (2001). Changes in premenstrual symptoms in women with schizophrenia: A prospective study. Psychosom Med 63: 822-829.
16. Clouston S (1906) Clinical lectures on mental disease. London.
17. Cyr M, Carlon F, Morissette M, DiPaolo T (2002) Estrogenic modulation of brain activity: Implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci 27: 12-27.
18. DeLisi LE, Dauphinais ID, Hauser P (1989) Gender differences in the brain: Are they relevant to the pathogenesis of schizophrenia? Compr Psychiatry 30: 197-208.
19. Diczfalusy E, Lauritzen C (1961) Östrogene beim Menschen. Springer, Berlin.
20. DiPaolo T (1994) Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 5: 27-42.
21. Fink G, Sumner BEH, McQueen JK, Wilson H, Rosie R (1998) Sex steroid control of mood, mental state and memory. Clin Exp Pharmacol Physiology 25: 764-775.
22. Fink G, Sumner BEH, Rosie R, Grace O, Quinn JP (1996) Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol 16: 325-344.
23. Forrest AD, Hay AJ (1971) Sex differences and the schizophrenic experience. Acta Psychiatr Scand 47: 137-149.
24. Garcia-Segura LM, Azcoitia I, DonCarlos LL (2001) Neuroprotection by estradiol. Progr Neurobiol 63: 29-60.
25. Gattaz WF, Vogel P, Riecher-Rössler A, Soddu G (1994) Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biol Psychiatry 36: 137-139.
26. Georgi F, Fels E (1933) Follikelhormonbestimmungen im Harn schizophrener Frauen. Z Gesamte Neurol Psychiatrie 147: 746-756.
27. Glick J, Stewart D (1980) A new drug treatment for premenstrual exacerbation of schizophrenia. Compr Psychiatry 21: 281-287.
28. Gordon JH, Borison RL, Diamond BI (1980) Modulation of dopamine receptor sensitivity by estrogen. Biol Psychiatry 15: 389-396.
29. Guy U (ed) (1976) ECDEU Assessmant manual for psychopharmacology, revised. DHEU Publication No. (ADM): 76-338. Rockville, National Institute of Mental Health.
30. Häffner R (1912) Beziehungen zwischen Menstruation und Nerven- und Geisteskrankheiten auf Grund der Literatur und klinischer Studien. Z Gesamte Neurol Psychiatrie 9: 154-223.
31. Häfner H, an der Heiden W, Behrens S, Gattaz F, Hambrecht M, Löffler W, Maurer K, Munk-Jørgensen P, Nowotny B, Riecher-Rössler A, Stein A (1998) Causes and consequences of the gender differences in age at onset of schizophrenia. Schizophr Bull 24: 99-113.
32. Häfner H, Behrens S, De Vry J, Gattaz F (1991) Oestradiol enhences the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. Evidence from an epidemiological study and from animal experiments. Eur ArchPsychiatr Clin Neurosci 241: 65-68.
33. Häfner H, Riecher-Rössler A, Maurer K, Fätkenheuer B, Löffler W (1992) First onset and early symptomatology of schizophrenia. A chapter of epidemiologicyl and neurobiological research into age and sex differences. Eur Arch Psychiatr Clin Neurosci 242: 109-118.
34. Halbreich U, Rojansky N, Palter S, Tworek H, Hissin P, Wang K (1995) Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry 37: 434-441.
35. Hallonquist JD, Seeman MV, Lang M, Rector NA (1993) Variation in symptom severity over the menstrual cycle of schizophrenics. Biol Psychiatry 33: 207-209.
36. Harris AH (1997) Menstrually related symptom changes in women with schizophrenia. Schizophr Res 27: 93-99.
37. Hautzinger M, Bailer M, Worall H, Keller F (1995) Beck-Depressions- Inventar (BDI). Testhandbuch, 2nd ed. Huber, Bern.
38. Hegar A (1884) Castration als Mittel gegen nervöse und psychische Leiden. Arch Gynäkologie 24: 318-323.
39. Hendrick V, Altshuler LL, Burt VK (1996) Course of psychiatric disorders across the menstrual cycle. Harvard Rev Psychiatry 4: 200-207.
40. Hoff AL, Kremen WS, Wieneke MH, Lauriello J, Blankfeld HM, Faustman WO, Csernansky JG, Nordahl TE (2001) Association of estrogen levels with neuropsychological performance in women with schizophrenia. Am J Psychiatry 158: 1134-1139.
41. Huber TJ, Rollnik J, Wilhelms J, von zur Mühlen A, Emrich HM, Schneider U (2001) Estradiol levels in psychotic disorders. Psychoneuroendocrinology 26: 27-35.
42. Jolly Ph (1915) Menstruation und Psychose. Arch Psychiatrie Nervenkrankheiten 55: 637-686.
43. Kafka V (1935) Hormone bei Schizophrenie. Wien Med Wochenschr 85: 30-31.
44. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
45. Kendell RE, Chalmers JC, Platz C (1987) Epidemiology of puerperal psychoses. Br J Psychiatry 150: 662-673.
46. Klinga K (1994) Determination of hormones and hormone receptors. In: Runnebaum B, Rabe T (eds) Gynecological endocrinology and reproductive medicine, vol 1. Springer, Berlin Heidelberg New York, 45-54.
47. König C, Linzenmeier G (1913) Ueber die Bedeutung gynäkologischer Erkrankungen und den Wert ihrer Heilung bei Psychosen. Arch Psychiatrie Nervenkrankheiten 51: 1002-1054.
48. Könnecke R, Häfner H, Maurer K, Löffler W, an der Heiden W (2000) Main risk factors for schizophrenia: Increased familial loading and pre- And peri-natal complications antagonize the protective effect of oestrogen in women. Schizophr Res 44: 81-93.
49. Kraepelin E (1909) Psychiatrie, Bd 1-4. Barth, Leipzig.
50. Krafft-Ebing R v (1878) Untersuchungen über das Irresein zur Zeit der Menstruation. Arch Psychiatrie Nervenkrankheiten 8: 65-107.
51. Krafft-Ebing R v (1903) Lehrbuch der Psychiatrie auf klinischer Grundlage für praktische Ärzte und Studierende, 7th ed. Ferd. Enke, Stuttgart.
52. Kretschmer E (1921) Körperbau und Charakter. Springer, Berlin.
53. Kulkarni J, deCastella A, Riedel A, Taffe J, Fitzgerald P, Burger H (2001) Estrogen - A potential new treatment in schizophrenia. Schizophr Res 48: 137-144.
54. Kulkarni J, deCastella A, Smith D, Taffe J, Keks N, Copolov D (1996) A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 20: 247-252.
55. Lansbury J, Hughes J (1939) Estrin excretion in psychotic patients. Am J Psychiatry 95: 1119-1125.
56. Lee SJ, McEwen BS (2001) Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. Annu Rev Pharmacol Toxicol 41: 569-591.
57. Leidenberger FA (1992) Klinische Endokrinologie für Frauenärzte. Berlin, Springer.
58. Lewine RRJ (1981) Sex differences in schizophrenia. Psychol Bull 90: 432-444.
59. Lewine RRJ, Strauss JS, Gift TE (1981) Sex differences in age at first hospital admission for schizophrenia: A fact or artifact? Am J Psychiatry 138: 440-444.
60. Lindamer LA, Buse DC, Lohr JB, Jeste DV (2001) Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry 49: 47-51.
61. Loranger AW (1984) Sex difference in age of onset of schizophrenia. Arch Gen Psychiatry 41: 157-161.
62. Mahé V, Dumaine A (2001) Oestrogen withdrawl associated psychoses. Acta Psychiatr Scand 104: 323-331.
63. Mall G (1958) On the hormonal treatment of pre- And postmenstrual ovarian psychoses. In: Reiss M (ed) Psychoendocrinology. Grune & Stratton, Orlando, 96-103.
64. Mall G (1960) Diagnostik und Therapie ovarieller Psychosen. Zentralbl Gesamte Neurol Psychiatrie 155: 250.
65. Mayer CEL (1872) Menstruation im Zusammenhange mit psychischen Störungen. Beiträge zur Geburtshülfe und Gynäkologie 1: 111-135.
66. Mayer CEL (1869) Die Beziehungen der krankhaften Zustände in den Sexualorganen des Weibes zu Geistesstörungen. Berlin.
67. McEwen BS, Alvers SE (1999) Estrogen actions in the central nervous system. Endocrine Rev 20: 279-307.
68. Melkersson KI, Hulting A-L, Rane AJ (2001) Dose requirement and prolactin elevation of anttipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 51: 317-324.
69. Morissette M, DiPaolo T (1993) Sex and estrous cycle variations of rat striatal dopamine uptake sites. Neuroendocrinology 58: 16-22.
70. Nilsson P (1939) Der Prolan- und Follikulingehalt des Harns bei schizophrenen Frauen mit in der Genitalsphäre lokalisierten taktilen Halluzinationen. Upsala Läkareförenings Förhandlingar 44: 495-504.
71. Notman MT, Nadelson CC (2002). The hormone replacement therapy controversy. Arch Women Ment Health 5: 33-35.
72. Nott PN (1982). Psychiatric illness following childbirth in Southampton: A case register study. Psychol Med 12: 557-561.
73. Oesterreicher W (1934) Die Ausscheidung des gonadotropen Hormons des Hypophysenvorderlappens und des weiblichen Sexualhormons (Follikelhormon) bei Manien, Depressionen und Schizophrenien im geschlechtsreifen Alter. Wien Klin Wochenschr 46: 1385-1388.
74. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Reports 10: 799-812.
75. Rabe T, Runnebaum B (1997) Hormones. In: Runnebaum B, Rabe T (eds) Gynecological endocrinology and reproductive medicine, vol 1. Springer, Heidelberg Berlin New York, 1-43.
76. Reiss M (ed) (1958) Psychoendocrinology. Grune & Stratton, Orlando.
77. Riecher-Rössler A (2003) Oestrogens and schizophrenia. Curr Opin Psychiatry 16: 187-192.
78. Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R (1994) Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 20: 203-214.
79. Ross SM (1909): Menstruation in its relationships to insanity. J Mental Sci 55: 270-280.
80. Sacerdoti G, Carry E (1955) Funzionalità epatica e reattivita cutanea agli estrogeni in schizofreniche con iperestrogenismo. Rivista di Patologia Nervosa e Mentale 76: 781-790.
81. Saethre H (1933) Titrierung von Sexualhormonen bei Geisteskranken. Klin Wochenschr 12: 1409-1410.
82. Salokangas RR (1983) Prognostic implications of the sex of schizophrenic patients. Br J Psychiatry 142: 145-151.
83. Sartorius N, Jablensky A, Shapiro R (1978) Cross-cultural differences in the shortterm prognosis of schizophrenic psychoses. Schizophr Bull 4: 102-113.
84. Sartorius N, Jablensky A, Korten A, Ernberg G, Anker M, Cooper JE, Day R (1986) Early manifestations and first-contact incidence of schizophrenia in different cultures. Psychol Med 16: 909-928.
85. Schaefer A (1894) Einfluss der Psychose auf den Menstruationsvorgang. Allg Z Psychiatrie Psychisch-gerichtliche Medizin 50: 976-996.
86. Schneider HPG (2002) The view of the International Menopause Society on the Women's Health Initiative. Climacteric 5: 211-216.
87. Schroeter R (1874) Die Menstruation in ihren Beziehungen zu den Psychosen. Z Psychiatrie 30: 551-572 (part 1); 31: 234-250 (part 2).
88. Sears HA, Morter RA, Simonsen M, Williams C (1937) Blood estrin level in schizophrenia. Am J Psychiatry 93: 1293-1303.
89. Seeman MV (1997) Psychopathology in women and men: focus on female hormones. Am J Psychiatry 154: 1641-1647.
90. Seeman MV (1996) The role of estrogen in schizophrenia. J Psychiatry Neurosci 21: 123-127.
91. Seeman MV (1985) Sex and schizophrenia. Can J Psychiatry 30: 313-315.
92. Seeman MV (1983) Interaction of sex, age, and neuroleptic dose. Compr Psychiatry 24: 125-128.
93. Seeman MV (1982) Gender differences in schizophrenia. Can J Psychiatry 27: 107-112.
94. Smith S, Wheeler MJ, Murray R, O'Keane V (2002) The effects of antipsychotic induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 22: 109-114.
95. Swanson DW, Barron A, Floren A, Smith JA (1964) The use of norethynodrel in psychotic females. Am J Psychiatry 120: 1101-1103.
96. The North American Menopause Society (2003) Estrogen and progestogen use in peri- And postmenopausal women: September 2003 position statement of The North American Menopause Society. Menopause 10: 497-506.
97. Tsuang MT, Dempsey GM, Rauscher FA (1976) A study of "atypical schizophrenia": Comparison with schizophrenia and affective disorder by sex, age of admission, precipitant, outcome, and family history. Arch Gen Psychiatry 33: 1157-1160.
98. Tukey JW (1977) Exploratory data analysis. Reading Mass., Addison-Wesley.
99. Turgeon JL, McDonnel DP, Martin KA, Wise PM (2004) Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304: 1269-1273.
100. Wells S (1886) Castration in mental and nervous diseases. A symposium by Sir T. Spencer Wells, Dr. Alfred Hegar and Robert Battey MD. Am J Med Sci 8: 455-471.
101. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 288: 321-333.
102. Writing Group of the International Menopause Society Executive Committee (2004) Guidelines for the hormone treatment of women in the menopause transition and beyond. Climacteric 7: 8-11.